ADC Therapeutics SA Share Price Today: Live Updates & Key Insights

ADC Therapeutics SA share price today is $3.86, up -4.46%. The stock opened at $4.12 against the previous close of $4.04, with an intraday high of $4.12 and low of $3.84.

ADC Therapeutics SA Share Price Chart

ADC Therapeutics SA

us-stock
To Invest in {{usstockname}}
us-stock

ADC Therapeutics SA Share Price Performance

$3.86 -0.0446(-4.46%) ADCT at 23 Mar 2026 11:53 AM Biotechnology
Lowest Today 3.84
Highest Today 4.12
Today’s Open 4.12
Prev. Close 4.04
52 Week High 4.98
52 Week Low 1.05
Day’s Range: Low 3.84 High 4.12
52-Week Range: Low 1.05 High 4.98
1 day return -
1 Week return -7.84
1 month return -12.13
3 month return +4.72
6 month return +11.99
1 year return +134.13
3 year return +94.72
5 year return -86.5
10 year return -

ADC Therapeutics SA Institutional Holdings

Redmile Group, LLC 12.46

Prosight Management, LP 6.74

Point72 Asset Management, L.P. 6.47

Orbimed Advisors, LLC 4.63

Nantahala Capital Management, LLC 4.35

BlackRock Inc 3.59

Morgan Stanley - Brokerage Accounts 2.92

Eventide Asset Management, LLC 2.68

Eventide Healthcare & Life Sciences I 2.68

iShares Russell 2000 ETF 1.68

Biotech Growth Ord 1.51

The Goldman Sachs Group Inc 1.27

TCG Crossover Management, LLC 1.11

Bank of America Corp 1.08

Lynx1 Capital Management, LP 1.05

State Street Corp 1.03

Junked Platinum Investment Management Ltd 0.92

Vanguard Group Inc 0.90

Geode Capital Management, LLC 0.79

Fidelity Small Cap Index 0.67

BNP Paribas Arbitrage, SA 0.66

iShares Biotechnology ETF 0.59

Blue Owl Capital Holdings LP 0.58

iShares Russell 2000 Growth ETF 0.57

Vantage Consulting Group Inc. 0.54

JPMorgan Chase & Co 0.53

State St Russell Sm/Mid Cp® Indx SL Cl I 0.41

Vanguard Russell 2000 ETF 0.33

Vanguard US Momentum Factor ETF 0.32

State St Russell Sm Cap® Indx SL Cl I 0.24

iShares Micro-Cap ETF 0.18

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.15

Stt Strt SPDR® Russell2000 US SmCapETF 0.12

NT R2000 Index Fund - DC - NL - 3 0.12

iShares Russell 2000 Small-Cap Idx Instl 0.10

Vanguard VIF Small Co Gr 0.09

Russell 2500™ Index Fund F 0.09

Spartan Small Cap Index Pool K 0.08

Nuveen Small Cap Blend Idx R6 0.08

ADC Therapeutics SA Market Status

Strong Buy: 4

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ADC Therapeutics SA Fundamentals

Market Cap 490.39 M

PB Ratio 2.5787

PE Ratio 0.0

Enterprise Value 368.95 M

Total Assets 323.15 M

Volume 2421483

ADC Therapeutics SA Company Financials

Annual Revenue FY23:69558000 69.6M, FY23:122566000 122.6M, FY22:209908000 209.9M, FY21:33917000 33.9M, FY20:0 0.0M

Annual Profit FY23:67029000 67.0M, FY23:119802000 119.8M, FY22:205329000 205.3M, FY21:32524000 32.5M, FY20:null 0.0M

Annual Net worth FY23:-240053000 -240.1M, FY23:-178507000 -178.5M, FY22:-155800000 -155.8M, FY21:-230026000 -230.0M, FY20:-246290000 -246.3M

Quarterly Revenue Q3/2025:16427000 16.4M, Q2/2025:18839000 18.8M, Q1/2025:23033000 23.0M, Q3/2024:18016000 18.0M, Q2/2024:17410000 17.4M

Quarterly Profit Q3/2025:15225000 15.2M, Q2/2025:18003000 18.0M, Q1/2025:20972000 21.0M, Q3/2024:17165000 17.2M, Q2/2024:15355000 15.4M

Quarterly Net worth Q3/2025:-40966000 -41.0M, Q2/2025:-56646000 -56.6M, Q1/2025:-38602000 -38.6M, Q3/2024:-43969000 -44.0M, Q2/2024:-36544000 -36.5M

About ADC Therapeutics SA & investment objective

Company Information ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Organisation Biotechnology

Employees 188

Industry Biotechnology

CEO Dr. Ameet Mallik M.B.A., M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ADC Therapeutics SA FAQs

What is the share price of ADC Therapeutics SA today?

The current share price of ADC Therapeutics SA is $3.86.

Can I buy ADC Therapeutics SA shares in India?

Yes, Indian investors can buy ADC Therapeutics SA shares by opening an international trading and demat account with Motilal Oswal.

How to buy ADC Therapeutics SA shares in India?

You can easily invest in ADC Therapeutics SA shares from India by:

Can I buy fractional shares of ADC Therapeutics SA?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ADC Therapeutics SA?

ADC Therapeutics SA has a market cap of $490.39 M.

In which sector does ADC Therapeutics SA belong?

ADC Therapeutics SA operates in the Biotechnology sector.

What documents are required to invest in ADC Therapeutics SA stocks?

To invest, you typically need:

What is the PE and PB ratio of ADC Therapeutics SA?

The PE ratio of ADC Therapeutics SA is N/A and the PB ratio is 2.58.